Skip to search formSkip to main contentSkip to account menu

CI 980

Known as: CI-980, CI980 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

canertinib dihydrochloridemivobulin isethionate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors
CI-980 is a synthetic mitotic inhibitor that binds to the colchicine binding site of tubulin. It demonstrates broad activity… 
2004
2004
Cellular transport of CI-980
SummaryCI-980, originally synthesized as a potential folate antagonist, is a tubulin-binding mitotic inhibitor currently in… 
2002
2002
CI-980 for the Treatment of Recurrent or Progressive Malignant Gliomas: National Central Nervous System Consortium Phase I–II Evaluation of CI-980
Objective: The purpose of this phase I/II trial was to determine the maximal tolerated dose of CI-980, and determine efficacy… 
2001
2001
Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy
Summary Malignant melanoma is increasing in frequency at a rapid rate in the United States. Metastatic disease is chemoresistant… 
1998
1998
Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma.
CI-980 is a synthetic mitotic inhibitor that binds to tubulin at the colchicine site, inhibiting the polymerization of… 
1998
1998
Phase II study of CI-980 (NSC 635370) in patients with previously treated advanced soft-tissue sarcomas
Doxorubicin and ifosfamide are the two most active agents in the treatment of soft-tissue sarcomas. Patients whose tumors have… 
1997
1997
Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent.
CI-980 (NSC 613862) is one of a novel class of 1,2-dihydropyrido[3, 4-b]pyrazines that inhibits tubulin polymerization… 
1997
1997
Electrophysiological effects of CI‐980, a tubulin binding agent, on guinea‐pig papillary muscles
The electrophysiological effects of CI‐980, a new tubulin‐binding agent that inhibits assembly of cytoplasmic microtubules, on… 
1995
1995
Differential effects of ethyl 5-amino-2-methyl-1,2-dihydro-3-phenylpyrido[3,4-b]pyrazin-7-yl carbamate analogs modified at position C2 on tubulin polymerization, binding, and conformational changes.
NSC 613863 (R)-(+) and NSC 613862 (S)-(-) (CI980) are two chiral isomers of ethyl 5-amino 2-methyl-1,2-dihydro-3-phenylpyrido[3,4… 
1994
1994
Tubulin Binding Agent CI‐980 Has Positive Inotropic and Local Anesthetic Actions
Tubulin binding agents inhibit tubulin polymerization by actions at specific binding sites. CI-980 acts at the colchicine-binding… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)